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Abstract
Proper functioning wound healing strategies are sparse. Adequate vascular formation to the injured area, as
well as replacement of the volume loss, is fundamental in soft tissue repair. Tissue engineering strategies have
been proposed for the treatment of these injury sites. Novel cell-free substance, human adipose tissue extract
(ATE), has been previously shown to induce in vitro angiogenesis and adipogenesis and in vivo soft tissue for-
mation. This study reports the translation of ATE preparation from laboratory to the operating room (OR).
ATE samples for this study were derived from adipose tissue obtained with the water-jet assisted liposuction
technique from 27 healthy patients. The variables studied included incubation time (15, 30, and 45min), tem-
perature (room temperature vs. 37C), and ﬁlter type to determine the optimal method yielding the most con-
sistent total protein content, as well as consistent and high expression of adipose-derived growth factors and
cytokines, including: vascular endothelial growth factor, basic ﬁbroblast growth factor, interleukin-6, adiponec-
tin, leptin, and insulin-like growth factor. Following the optimization, samples were produced in the OR and
tested for their sterility. No signiﬁcant differences were observed when comparing extract incubation time
points or incubation temperature. Nonetheless, when studying the different ﬁlter types used, a syringe ﬁlter
with PES membrane with larger ﬁlter area showed signiﬁcantly higher protein concentration ( p £ 0.018).
When studying the different growth factor concentrations, ELISA results showed less variation in cytokine con-
centrations in the OR samples with the optimized protocol. All of the OR samples were tested sterile. The de-
vised protocol is an easy and reproducible OR-ready method for ATE generation. As an attractive source of
growth factors, ATE is a promising alternative in the vast ﬁeld of tissue engineering. Its clinical applications
include volume replacement as a complement to ﬁllers and improvement of the permanence of fat grafts
and wound healing, among other bioactive functions.
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Introduction
Currently, the major challenge in tissue engineering lies
not only in the high costs of material production and
safety of the biomaterial used but also most impor-
tantly in the lack of efﬁcacy in promoting vascular
formation and soft-tissue replacement.1–4 In particular,
neovascularization induction is a major obstacle for de-
veloping tissue engineering strategies.5–9
Mature human adipose tissue, considered an endo-
crine entity on its own, is a known source of growth
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and differentiation promoting factors.10–16 These
growth factors have the ability to induce proliferation,
migration, and differentiation of various cell lines.13–17
Extensive functions and clinical applications of growth
factors are well reported in the literature.18–24 Adipose
tissue is an excellent source of adipose stem cells in ad-
dition to the adipose-derived growth factors,11,25–30
and human adipose tissue is easily available through
liposuction.
We have previously developed an acellular bioac-
tive extract from mature adipose tissue, proven to
contain important adipose tissue cytokines, including
vascular endothelial growth factor (VEGF), basic ﬁ-
broblast growth factor beta (FGFb), interleukin 6
(IL-6), insulin-like growth factor 1 (IGF-1), adipo-
nectin, and angiogenin, among others.31,32 This ex-
tract demonstrates a unique capacity of inducing
angiogenesis and adipogenesis.31
Animal experimental models indicated that, in com-
bination with hydrogel, this adipose tissue extract
(ATE) promoted neovascularization and soft tissue ex-
pansion. In addition, it was shown that the permanence
of the effect of the extract remained for 9 months. Fur-
thermore, during short- and long-term follow-up, no
hypersensitivity or foreign body reactions were reported
with human extract in rat experimental models.32
When aiming at using this autologous extract in
clinical studies, the development of a straightforward
and reliable method for operation room preparation
is essential. ATE was previously produced from solid
mature adipose tissue and shown to be bioactive
in vitro and in vivo.31,32 In the current study, ATE
was produced from lipoaspirate material. This simple
surgical procedure and operating room (OR) prepara-
tion would make ATE an attractive source of multiple
growth factors and cytokines with a plethora of fu-
ture applications.32
In vitro, these growth factors have demonstrated the
induction and differentiation of adipocytes, endothe-
lial cells, keratinocytes, chondrocytes, and osteoblasts,
among others involved in tissue regeneration.31,33,34
The potential of ATE for different applications holds
value in areas where soft tissue formation and volume
are required, especially in volume loss and potentially
for optimizing fat grafting permanence.32
In this study, the optimal method of human fat ex-
tract preparation was investigated with different vari-
ables, such as incubation time, temperature, and ﬁlter
type. These characteristics were considered key when
transferring the methodology from the laboratory to
the OR while meeting the clinical and surgical stan-
dards. The goal was to develop a protocol that meets
clinical standards that allow the surgeon to prepare
the ATE in the OR for immediate application and
translate the ATE laboratory protocol for clinical ther-
apeutic use.
Materials and Methods
Ethical aspects
The study was conducted according to the Declaration
of Helsinki, the European Guidelines on Good Clinical
Practice, and was approved by the Ethics Committee of
the Pirkanmaa Hospital District, Tampere, Finland
(R03058). The human adipose tissue samples were
obtained from surgical operations with informed con-
sents at the Tampere University Hospital, Tampere,
Finland.
Samples
Human adipose tissue samples were obtained through
the water-assisted liposuction technique (body-jet;
Human Med AG, Germany) and processed under ster-
ile conditions. A total of 27 patients were included in
the study. The main indications for liposuction in
these patients were fat grafting and body contouring.
Exclusion criteria for the donors were patients receiv-
ing hormonal therapy, after cancer ablative surgery,
active cancer, recent chemotherapy treatment, and
comorbidities that contraindicated the surgery. All sur-
geries were uneventful, and no complications were
reported. All tested samples were from female patients,
and their mean age, weight, and body mass index are
listed in Table 1. Lipoaspiration was performed in the
abdominal subcutaneous tissue in 76.2% of the pa-
tients, from the ﬂank region in 19% and from the
thigh in 4.7%.
Lipoaspiration procedure
Liposuctions were performed under general or spinal
anesthesia using the water-assisted technique (body-
jet, Human Med AG, Germany). Tumescent solution
containing 1mg of adrenaline and 250mg of lidocaine
per 1000mL saline was inﬁltrated. The pressure of in-
ﬁltration and suction was done at a range of 2 or 3 (50
Table 1. Patient Demographics
Mean value Range
Age 51.95 33–68
Weight 77.1 57–94
Body mass index 28.1 21–38
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or 70 bar). Lipoaspiration was performed under
400mbar pressure. As a guide, range 2 is equivalent
to 110mL/min and a range 3 to 130mL/min of tumes-
cent jet emission. Adipose tissue collection was done
under a sterile environment into a canister (LipoCol-
lector, Human Med, Germany) and transferred to
50mL syringes. The amount of fat aspirated for sam-
pling varied from 40 to 100mL per patient.
Production of ATE in the laboratory
In the laboratory, ATE was produced by adding Ringer
lactate (BaxterHealthcareCorporation,Helsinki, Finland)
to the adipose tissue sample at an approximate ratio of 1:1
and then processed according to the different study vari-
ables. Incubation was performed at 37C water bath or
at room temperature (RT). The incubation times studied
were 15, 30, or 45min. After incubation, the samples
were sterile ﬁltered with different 0.2lmpore size syringe
ﬁlters (Acrodisc ﬁlter, polyethersulfone PES membrane
[PALL Life Sciences, New York]; Minisart NML ﬁlter,
cellulose acetate membrane [Sartorius AG, Germany];
Filtropur S Plus ﬁlter, cellulose acetate membrane [Sar-
stedt & Co, Germany]; and Millex GP ﬁlter, PES mem-
brane [Merck, Millipore, Germany]). Once ﬁltered, the
ATE was stored at 20C until sample analysis.
Production of ATE in the OR
ATE production was performed on a separate sterile
bench in the OR. After performing the lipoaspiration,
the adipose tissue was gently mixed with prewarmed
(37C) Ringer lactate solution at an approximate ratio
of 1:1. The mixture was incubated for 30min at RT.
The lower layer containing the Ringer lactate solution
was passed through a sterile ﬁlter and frozen at 20C
until further use. The preparation method of ATE is
summarized in Figure 1. ATE samples have previously
been shown to induce adipogenesis from 200lg/mL up-
wards in cell culture.31,32 Thus, total protein concentra-
tion of 200lg/mL was selected as the lowest acceptance
limit of ATE samples. ATE samples prepared in the lab-
oratory and OR originated from different donors.
Sterility test of OR samples
Sterility test was performed from six ATE samples pre-
pared in the OR. Approximately, 2mL of ATE was
added per BacT/ALERT system (bioMe´rieux SA, France)
bottle. Aerobic BacT/ALERT SA and anaerobic bacteria
testing BacT/ALERT SN (i.e., gram-positive and gram-
negative bacteria and yeast) were performed for each
ATE sample. Samples were cultured in BacT/ALERT
3D (bioMe´rieux SA) for 10 days before analyzing bacte-
rial growth. ‘‘Negative’’ results in the system indicated
that there was no bacterial or yeast growth.
Measurement of protein concentration
Total protein content of the samples was measured using
PierceBCAProteinAssayKit (ThermoScientiﬁc,Wal-
tham, MA) according to manufacturer’s instructions
using bovine serum albumin (BSA) as a standard. Results
weremeasured after 30min incubation at 37Cat 562nm
with Varioskan FlashMultimode Reader (Thermo Sci-
entiﬁc).
Measurement of growth factor concentration
Extract samples were tested with colorimetric sandwich
ELISA, Custom made ELISA strips (Signosis, Santa
Clara, CA). The following cytokines were evaluated:
VEGF, tumor necrosis factor alpha (TNFa), interferon
FIG. 1. Steps for ATE preparation. Step 1, Liposuction and collection of adipose tissue with water-assisted
liposuction. Step 2, Transfer of fat into syringes and addition of Ringer solution. Step 3, 30min incubation and
ﬁltration to produce sterile ATE, which is ready for clinical use. ATE, adipose tissue extract.
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gamma (IFNc), granulocyte colony stimulating factor (G-
CSF), granulocyte macrophage colony stimulating factor
(GM-CSF), IL-6, IL-8, IGF-1, IL-1a, FGFb, resistin, mac-
rophage inﬂammatory protein (MIP-1), adiponectin, lep-
tin, and rantes. Protein standards for custom human
cytokine ELISA Strip (Signosis) were used with concen-
trations of 2 and 1ng/mL. The ELISA strips were used
according to manufacturer’s instructions as follows. To
each well, 100lL of the studied ATE batch was added
and incubated for 1 h with gentle shaking in RT. The liq-
uid was then aspirated from each well and the wells were
washed thrice with 200lL of assay wash buffer per well.
Subsequently, 100lL of Streptavidin-HRP conjugate di-
luted 1:200 in diluent buffer was added to each well and
incubated for 45min at RT under gentle shaking. After
incubation, the wells were washed thrice with 200lL of
washing buffer. One hundred microliters of substrate
was added in each well and then incubated between 5
and 30min per cytokine. The reaction was ended
with the addition of 50 lL of stop solution to each
well row simultaneously and detecting a visible color
change of the standard. The optical density was deter-
mined at 450 nm with Varioskan Flash multimode
reader (Thermo Scientiﬁc).
Statistical analyses
Statistical analyses were performed and graphs pro-
cessed with GraphPad Prism 5.0 (GraphPad Software,
Inc., San Diego, CA). The results were reported as
mean – SD, and differences were considered signiﬁcant
when p < 0.05*, p< 0.01**, and p < 0.001***. Results of
total protein concentration in incubation temperature
comparison and laboratory versus OR production of
ATE were analyzed with student’s t-test and two-tailed
posttest. The analyses of incubation time and ﬁlter type
used were performed using One-way ANOVA with
Tukey’s posttest. The relationship of growth factor con-
centrations in OR samples to laboratory samples was
calculated with Pearson’s correlation and results
depicted as r values.
Results
The effect of incubation temperature
The effect of incubation temperature onATE protein con-
centration was studied with a cellulose acetate membrane
ﬁlter (Sarstedt, Germany) used in our previous in vitro
studies.31 No signiﬁcant difference in total protein con-
centration was observed between RT incubation and
37C water bath incubation (Fig. 2A). However, there
was a slightly higher concentration of total protein in
water bath incubated samples compared to RT incubated
samples.
The effect of incubation time
Incubation times of 15, 30, and 45min were studied to de-
termine the shortest time for OR ATE extraction (consid-
ering possible immediate clinical use) in reference to
protein yield. Incubationwas performed in RT and the ex-
tract passed through a cellulose acetate membrane ﬁlter
(Sarstedt, Germany).31 The total protein concentration
between the time points did not differ signiﬁcantly (mul-
tiplicity adjusted p‡ 0.992, Fig. 2B), but the protein yield
showed less variation and slightly higher values in the
30min time point.
Filter testing
To estimate whether the protein yield varied among
different ﬁlter membranes, four different 0.2 lm ﬁlters
were selected. ATE was produced at 30min incubation
at RT and subsequently strained through the ﬁlters.
Close to 1000lg/mL protein was obtained with all ﬁl-
ters, but with polyethylene sulfone (PES) membrane
and largest surface area, showed a signiﬁcantly higher
protein yield (multiplicity adjusted p £ 0.018) com-
pared to the other ﬁlters (Fig. 3).
Transfer of the extraction protocol
from laboratory to the OR
To transfer the laboratory methodology to the OR,
ATE was produced at RT incubation for 30min and
subsequently ﬁltered with PES membrane. The results
in Figure 4 show that the samples produced in the lab-
oratory had greater deviation yet higher protein con-
centrations. However, these were not signiﬁcantly
higher than the OR samples ( p 0.0730, medians 1210
and 321.5, respectively).
Growth factor content of the samples
To control the quality and assure the bioactivity of the
samples, growth factor measurements of both laboratory
and OR samples were studied. The results show that the
growth factor yields were comparable between the sam-
ples produced in the laboratory and those from the OR
(Fig. 5) although the correlations varied between the
growth factors (Fig. 5). The samples had less variation
when performed in the OR with the optimized protocol
(Fig. 5). Most of the growth factors correlated well with
laboratory samples and in addition, VEGF (also higher
CV) and G-CSF produced higher mean growth factor
concentrations in the OR with the optimized protocol.
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Sterility test
A sterility test was performed to ensure asepsis of
the samples in the OR. All ATE samples were
negative for bacterial growth in aerobic and an-
aerobic media.
Discussion
One of the main challenges in tissue engineering is to
discover a bioactive source of growth factors with
regenerating properties while accelerating local action,
enhancing volume replacement and stimulating the
growth of multiple cell lines.13,35–38 The most impor-
tant feature is to rapidly induce tissue neovasculariza-
tion to avoid hypoxia and ischemia.39–43 Ideally, this
bioactive material should also be cost beneﬁcial, easy
to prepare, and reproducible. In our previous studies,
we have been able to isolate a novel cell-free bioactive
substance, ATE, which not only induces angiogenesis
and adipogenesis in vitro and in experimental models
but also is rich in growth factors.31,32 The advantage
of the current growth factor material is that as it does
not contain cells, it should have less immune reactions
and its allogeneic use could be possible. This would
ease its clinical use. As ATE is a large mixture of growth
factors, it has potential for better bioactivity. Clinicians
are still struggling to improve adipose tissue transfer
viability and working on ways to improve wound heal-
ing, scenarios that would beneﬁt from growth factor
use.
The main aim of the current study was to transfer
the method of obtaining adipose tissue growth factors
from the laboratory to the OR for later successful clin-
ical use. ATE has previously shown to induce soft tissue
formation when incorporated into hyaluronic acid and
is therefore a very promising material for soft tissue re-
placement and soft tissue healing.31,32 The authors
compared previously used parameters, protein yield,
and growth factor content and focused on modiﬁable
parameters when transferring the methodology from
the laboratory to the clinic. The variables contemplated
in this study were incubation time, incubation temper-
ature, and ﬁlter type. During the translation process of
ATE production from the laboratory to the OR, there
are high clinical demands to be met not only from
the clinical materials used but also to make this a sim-
ple method from surgical staff’s point of view. Because
in previous studies,31,32 whole solid fat was processed
in the laboratory to obtain ATE, it was crucial to
FIG. 2. (A) Protein concentration obtained in 37C and RT incubation. Comparison of total protein content of
the ATE samples in different incubation temperatures. ATE was incubated for 30min in 37C or RT and ﬁltered
with cellulose acetate Filter 3. No signiﬁcant difference was observed between incubation temperatures when
statistically evaluated with student’s t-test with two-tailed posttest ( p 0.7207) and n = 3. (B) Protein
concentrations obtained with 15, 30, and 45min incubation. Comparison of total protein content of the ATE
samples with incubation times of 15, 30, and 45min. ATE was produced in equal conditions except for
incubation time, that is, incubation was performed in RT and ﬁltered with Filter 3. No signiﬁcant difference was
observed between incubation times when statistically evaluated with one-way ANOVA with Tukey’s posttest
( p 0.9923) and n = 3. RT, room temperature.
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discover an easy method that would preserve an ade-
quate protein yield.
This transfer method is not only important but also
complicated and the impact of these variables had to
be determined. Therefore, our aim was to maintain
growth factor yields comparable to our previous stud-
ies, in a repeatable scenario. Moreover, our original
studies were performed with solid adipose tissue that
underwent processing, so we veriﬁed that the resulting
ATE would, in fact, yield similar results when originat-
ing from lipoaspirates. As a lipoaspiration method, we
used the water-assisted technique, which has been stan-
dardly used in our clinic due to its simplicity, and
demonstrated adipose tissue viability preservation.44
Although the technique uses the power of water at cer-
tain pressures, it is gentle enough to preserve adipo-
cytes with minimal tissue injury or blood loss. In
addition, patient recovery is quicker and morbidity
lower than traditional liposuction.45,46
In the current study, we optimized the preparation
protocol of ATE to translate the production from the
laboratory to the OR, studying three main variables.
To begin with, incubation time is important consider-
ing the time the patient was in surgery under local, spi-
nal, or general anesthesia. In ideal conditions, surgical
time should be as short as possible to prevent patient
perioperative complications and this is the reason
why the time points of 15, 30, and 45min were selected.
Furthermore, because original ATE samples were incu-
bated either in water bath or 37C incubator, we found
that comparing it to RT would offer the surgeon an eas-
ier method to produce ATE. In relation to the ﬁlter,
during the translation process, we noticed that operat-
ing theaters use a variety of materials of high clinical
standard demands. In our laboratory studies, we used
ﬁlters that were not applicable to the OR environment;
therefore, the challenge was to test those that did meet
these standards while preserving the protein yield. The
protocol was tested with four different ﬁlters with PES
and cellulose acetate membranes. We noticed that al-
though a larger ﬁlter area played a role, it seemed
that the hydrophilic low-protein binding nature of
the PES ﬁlter demonstrated advantages. Different to
FIG. 4. Protein concentrations obtained in OR
versus laboratory. Comparison of total protein
content between the ATE samples produced in
laboratory and those produced in OR. ATE was
incubated for 30min in RT and ﬁltered with PES
Filter 1. No signiﬁcant difference was observed
between the total protein of the two production
conditions as evaluated by student’s t-test with
two-tailed posttest ( p 0.0922) and n ‡ 6. OR,
operating room.
FIG. 3. Protein concentrations obtained with
four different ﬁlters. Comparison of total protein
concentration when ATE was produced with
30min incubation at RT using four distinct ﬁlters;
PES Filter 1 (7.5 cm2), cellulose acetate Filter 2
(6.2 cm2), cellulose acetate Filter 3 (5.3 cm2), and
PES Filter 4 (4.5 cm2). Statistical analysis was
performed with One-way ANOVA with Tukey’s
posttest, p < 0.05* and p < 0.01** and n= 4.
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previous publications, we used lipoaspirate material
that contains particles that easily clog ﬁlters, which
also led us to choose the adequate PES ﬁlter type. How-
ever, we recognize that interpersonal variations play a
great inﬂuence in the ﬁnal protein yield. The optimiza-
tion showed to reduce the variation between the sam-
ples and the speciﬁc growth factor concentrations
were not lost during the protocol modiﬁcations. In ad-
dition, the samples produced in the OR passed the ste-
rility tests performed.
By studying the effect of incubation temperature (RT
vs. 37C) and time (15, 30, and 45min), we showed
that the protocol is ﬂexible enough to be performed
in the busy OR setting without compromising the qual-
ity of the product.
When studying the protein yield, we observed that
adequate amounts were obtained in short incubation
times (15, 30, and 45min); yet we settled for 30min
as slightly higher protein concentrations were achieved
from this time point onward. Interestingly, tempera-
ture variations did not seem to affect total protein
and cytokine yields. We noticed that although the ﬁlter
characteristics may play a role, sample handling had an
important effect on the protein yield. Samples that had
to be neglected from the study (protein concentration
<200 ng/mL, four samples) were performed in the lab-
oratory, and thus, the time from the surgery to the
preparation of ATE varied. This was based on previous
studies where bioactivity was proven above this con-
centration of protein.31,32 Nonetheless, the ﬁlter mate-
rial or surface area of the ﬁlter may also have an impact
on the protein concentration and, therefore, on the fea-
sibility of the ATE production procedure.
We observed lower variations in growth factor and
cytokine measurements in the samples produced in
OR compared with the laboratory samples. It is well
known that interindividual differences in cytokine con-
centrations from freshly prepared primary cells are
usually much higher than the variations seen with re-
peated preparations of the same donor.47 There is an
inevitable patient-related variation due to the effects
of body mass index, age, weight, comorbidity, and lipo-
suction site that may affect protein yield, but the opti-
mization of the protocol was successful in decreasing
the sample-to-sample variation. The growth factor re-
sults are also in concordance with our previous studies
at 1-h incubation.32
Since ATE is prepared from autologous adipose tis-
sue, theoretically there are no risks for disease trans-
mission, immunogenic reactions, or cancer. This
solution is eluted from the ﬁlter, providing a cell-free
enriched fraction of biologically active mediators
(VEGF, IGF-1, etc.), most of which are key in wound
healing. The most abundant adipokines released by ad-
ipocytes, leptin, and adiponectin,48,49 as well as IGF-I,
were also predominant in this study. Inﬂammation-
FIG. 5. Speciﬁc protein concentrations in OR vs. laboratory. Analysis of 16 different adipokines in samples
produced in laboratory in optimization phase versus samples produced in OR after optimization. Adipokines
analyzed were VEGF, IL-6, adiponectin, leptin, rantes, FGFb, resistin, IL-8, MIP-1, TNFa, IFNc, G-CSF, GM-CSF,
IGF-1 and IL-1a. Results depicted as mean – SD, n ‡ 6.
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related factors observed by other investigators included
leptin, resistin, adiponectin, TNFa, IL-6, and plasmin-
ogen activator inhibitor-1.50 In obese individuals, there
is an increased expression of pro-inﬂammatory cyto-
kines such as TNFa, TGFb, and IL-6.51 In our previous
studies, FGFb, IGF-I, and IL-6 seemed to suggest the
adipogenic and angiogenic potential of ATE.31,32
VEGF initiates angiogenesis,52 while IGF-1 and FGFb
promote wound healing.53 However, determining the
optimal growth factor cocktail for adipogenesis and an-
giogenesis is challenging. Therefore, both the total pro-
tein concentration measurement and a set of growth
factors measured should be kept as a quality assurance
method also in further studies regarding ATE.
It is the authors’ belief that the main point of this study
was to conserve the growth factor yield when transferring
from a laboratory methodology to an OR setting. Varia-
tions in growth factor concentrations are multifactorial,
but we believe that interpatient variations play an impor-
tant role. Therefore, we focused on maintaining protein
yield compared to previous publications31,32 that demon-
strated proven biological activity.
The protocol optimization showed that ATE is easily
produced in the OR with a simpliﬁed method that pre-
serves sterility and lays the foundation to implement
ATE into the clinical setting. One of the major goals
of this development process was to ﬁnd acceptable
range of variability for an optimal ATE preparation,
without compromising the time pressure of a surgical
setting. A distinct advantage of ATE is that it not
only is prepared freshly from each patient for immedi-
ate use (e.g., treat wounds) but also that it can be frozen
and used for sequential treatments. This eliminates the
need for consecutive surgeries substantially reducing
the surgeon’s workload and also increasing patient
comfort. 47 Material OR requirements for ATE prepa-
ration are minimal and the need for centrifugation or
activation is bypassed. The fact that sufﬁcient protein
content can be obtained in an even shorter incubation
time than studied earlier32 and under RT makes ATE a
more attractive choice for clinicians compared to cur-
rently used products.
Orthobiologics is a relatively new science that in-
volves application of naturally found materials
from biological sources (e.g., cell-based therapies)
and offers exciting new possibilities to promote and
accelerate bone and soft tissue healing.54,55 The
goal of this discipline is to enhance the body’s innate
ability to repair and regenerate.55 In fact, the induc-
tive microenvironment has previously shown to en-
hance migration of adipose stromal cells in the
surrounding tissue and stimulate the cells to differen-
tiate into mature adipocytes.56 Growth factors are
known to play essential roles in wound repair and
may hold the key to successful healing. However,
the use of single cytokines has generated disappoint-
ing results compared to a combination of these.47,57
Therefore, it is evident that wound healing is a very
complex process that relies on the harmonious action
of a myriad of growth factors. This is a fundamental
principle in wound healing.47 The use of secretory
factors from adipose tissue to inﬂuence the wound
microenvironment may be a feasible approach to de-
velop topical applications for quicker repair.58 We
suggest the use of adipose tissue secretome to pro-
duce an extract rich in cytokines for topical applica-
tion of wounds, rather than using the difﬁcult process
of enriching the patients’ stem cells in vitro.58 Bur-
densome steps, including the use of collagenase for
digestion of tissue to isolate stem cells, would be ob-
viated when generating ATE, an important advan-
tage in the clinical setting.58 To date, adipose tissue
is already used as an active bio dressing to treat
wounds with promising wound healing results.58,59
Similarly, adipose tissue and its secretome have pos-
itively inﬂuenced wound healing and tissue regenera-
tion.60,61 In fact, the speed and quality of wound healing
have been enhanced signiﬁcantly in wounds treated with
adipose tissue-derived factors.58,60 In vitro, the condi-
tioned medium of adipose tissue composed of a multi-
tude of adipokines and growth factors, proved to
potently induce the proliferation of adipose stem cells
and endothelial cells, comparable to the conditioned
medium of stem cells.59,62
The potential clinical use of ATE is currently under
study in different clinical applications where growth fac-
tor may be required to enhance tissue vascularization,
healing, cell migration, growth, and proliferation. The
use of ATE would grant the beneﬁts of a cell-free ap-
proach and would, therefore, have a more extended
scope, not just limited to autologous application.58
Furthermore, it would make the production of an off-
the-shelf product according to good manufacturing prac-
tice much easier. Especially for the potential clinical appli-
cations of adipose tissue, the effect of its secretome needs
to be investigated thoroughly.58 In addition, the proan-
giogenic effect reported in this study may pose as an at-
tractive starting point for investigating the potential
impact of adipose tissue secretory factors on neovascula-
rization in several tissue regeneration applications.
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Conclusion
ATE is a very promising bioactive agent for a plethora of
clinical uses. The relative ease of preparation, applicability
in the clinical setting, favorable safety proﬁle, and possible
beneﬁcial outcome make ATE a promising therapeutic
approach for future regenerative treatments. It is easy to
obtain, inexpensive, and by being autologous and cell-
free, it is minimizing common problems of tissue engi-
neering. Its proven adipogenic and angiogenic properties,
along with being an abundant source of growth factors,
make ATE an appealing microenvironment for cell pro-
liferation, migration, and differentiation. Under these cir-
cumstances, any clinical scenario in need of tissue volume
addition, wound healing, and adequate vascularization
would beneﬁt from ATE. The consistent protein and
growth factor concentrations prove the repeatability of
the method, and thus, the extract production method
can be successfully produced in the OR environment
and is now ready for clinical research.
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